Albert Bourla, Pfizer CEO (Lintao Zhang/Getty Images)
October 10, 2024 11:15 AM EDTUpdated 01:49 PM
People
Pharma

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Drew Armstrong

Executive Editor

Max Bayer

Pharma Reporter

The mes­sage over the week­end to Pfiz­er’s CEO Al­bert Bourla was blank. But it con­tained a warn­ing nonethe­less.

It came from his for­mer CFO Frank …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times